Treatment of Diabetic Nephropathy with Chronic Kidney Disease and a History of Non-Cardioembolic Ischemic Stroke or TIA
This protocol applies to patients with type 1 or type 2 diabetes mellitus who also have chronic kidney disease (CKD) and have experienced a prior non-cardioembolic ischemic stroke or transient ischemic attack — a combination requiring a specific, structured secondary prevention strategy.
Clinical Scenario
The patient presents with T1D or T2D, established CKD, and a documented history of non-cardioembolic ischemic stroke or transient ischemic attack. This triad shapes both the treatment selection and the long-term management goals, with stroke recurrence prevention as the central objective.
Treatment Approach (Partial Overview)
Management involves antiplatelet therapy — initially a dual-agent regimen in the period following the acute event, subsequently consolidating to a long-term single-agent strategy. The complete protocol, including agent selection, sequencing, and transition criteria, is available in the full structured regimen.
References
DOI: 10.1016/j.nefro.2024.11.002
In patients with T1D or T2D and CKD and a previous non-cardioembolic ischemic stroke or transient ischemic stroke, the long-term use of antiplatelet therapy to reduce the risk of recurrent stroke is recommended.
Dual antiplatelet therapy (with low-dose aspirin and a P2Y12 inhibitor) after acute non-cardioembolic ischemic stroke/transient ischemic attack in patients with T1D or T2D and CKD followed by single antiplatelet therapy should be considered.
View source ↗